Joint
initiative
This website is an initiative of the Dutch CAA Foundation, the HCHWA-D Association and Leiden University Medical Center (LUMC).
024
participate in TRACK DCAA
Mivelsiran, formerly known as ALN-APP, is a RNA therapy that is being developed by Alnylam. Recently a phase II study with the drug has started, enrolling sporadic CAA patients on 3 sites. People with Dutchtype CAA, both sympotomatic and presymptomatic genecarriers, are able to participate in the study in Perth. Read everything you need to know when thinking about enrolling here.
Requirements for participation
You are eligible to participate in TRACK DCAA if:
We make sure that you will never find out your genetic status if you do not want to know! The research team will test your blood for the gene, but these results are blinded, so the research team does not know the genetic status of individuals. We want to be a 100% sure there is no way for you to find out by accident.
If need more information or have questions you want to talk through, our confidant Sanne van Rijn can speak to you first. She will take the time to answer your questions and talk you through what participation entails.
This website is an initiative of the Dutch CAA Foundation, the HCHWA-D Association and Leiden University Medical Center (LUMC).
participate in TRACK DCAA